17 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Mycobacterium tuberculosis ... infection (TB) ... A and B virus infection ... HIVAIDS #IDSA #management ... #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Mycobacterium tuberculosis ... infection (TB) ... A and B virus infection ... HIVAIDS #IDSA #management ... #pharmacology
Adjuvant therapies in critical care: steroids to treat infectious diseases
 - Severe Community Acquired Pneumonia
steroids to treat infectious ... meningitis - Tuberculous ... meningitis - Tuberculous ... #Pharmacology # ... Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
infections/year ... for 4.6% of new infections ... unable to limit infection ... HIV-infected patients should ... TB #Diagnosis #Management
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
infections/year ... for 4.6% of new infections ... unable to limit infection ... HIV-infected patients should ... TB #Diagnosis #Management
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Papillomavirus Infections ... HIV aged 21–29 should ... • Pap test should ... Prevention #Treatment #management ... #HIVAIDS #pharmacology
Flutycosine - Antibiotics Class Overview
 - 
Mechanism: 5-FC interferes with DNA and protein synthesis.  Only
B for initial management ... severe fungal infections ... severe candidal infections ... - Drug levels should ... #Pharmacology #Antibiotics
Drugs Used for the Treatment of COVID-19 Infection

** Editor Note (from ophthalmology MD input) - Hydroxychloroquine/chloroquine
Treatment of COVID-19 Infection ... Hydroxychloroquine/chloroquine should ... macular pathology" should ... Treatment #COVID19 #Pharmacology ... #Table #Management
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
Total dose should ... Tocilizumab should ... respiratory tract infection ... Siltuximab #COVID19 #Pharmacology ... #Management #Medications
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Multi-Drug Resistant Tuberculosis ... are contacts of infectious ... isolate DST result should ... #MDRTB #management ... antimicrobials #regimens #pharmacology